ReviewEJNMMI radiopharmacy and chemistry2017
Strategies to facilitate the discovery of novel CNS PET ligands.
Review in EJNMMI radiopharmacy and chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 75 citations in OpenAlex.
- A‑iMPO: A Design-Time Prediction Toolbox for Blood Brain Barrier Permeation Using an Integrated and Interpretable Multiparameter Optimization Framework.ACS medicinal chemistry letters · 2026Article
- A Holistic Approach to Identifying a Positron Emission Tomography (PET) Tracer Candidate for In Vivo Imaging of Purinergic P2X7 Receptor in Neuroinflammation.ACS pharmacology & translational science · 2026Article
- Discovery of Pyrazole-Based Positron Emission Tomography Agent that Maps Histone Deacetylase 6 (HDAC6) in the Nonhuman Primate Brain.Journal of medicinal chemistry · 2025Article
- Spatial Distribution of Brain PET Tracers by MALDI Imaging.Journal of the American Society for Mass Spectrometry · 2025Article
- Enhancing Blood-Brain Barrier Penetration Prediction by Machine Learning-Based Integration of Novel and Existing, In Silico and Experimental Molecular Parameters from a Standardized Database.Journal of chemical information and modeling · 2025Article
- GDNF and cAMP significantly enhanceHeliyon · 2024Article
- Photoredox Nucleophilic (Radio)fluorination of Alkoxyamines.Journal of the American Chemical Society · 2024Article
- Medicinal (Radio) Chemistry: Building Radiopharmaceuticals for the Future.Current medicinal chemistry · 2024Review
- Review
- Peering into the Brain's Estrogen Receptors: PET Tracers for Visualization of Nuclear and Extranuclear Estrogen Receptors in Brain Disorders.Biomolecules · 2023Article
- Discovery of [ACS medicinal chemistry letters · 2023Article
- Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas.Molecules (Basel, Switzerland) · 2023Review
- Pretargeted imaging beyond the blood-brain barrier.RSC medicinal chemistry · 2023Article
- Positron Emission Tomography of Neuroimmune Responses in Humans: Insights and Intricacies.Seminars in nuclear medicine · 2023Review
- Review
- Synthesis, Biological Evaluation, and Docking Studies of Antagonistic Hydroxylated Arecaidine Esters Targeting mAChRs.Molecules (Basel, Switzerland) · 2022Article
- The Application ofFrontiers in nuclear medicine · 2022Review
- Artificial Intelligence and the Future of Diagnostic and Therapeutic Radiopharmaceutical Development:: In Silico Smart Molecular Design.PET clinics · 2021Review
- Drug Penetration into the Central Nervous System: Pharmacokinetic Concepts and In Vitro Model Systems.Pharmaceutics · 2021Review
- The Non-Anhydrous, Minimally Basic Synthesis of the Dopamine DChemistry (Basel, Switzerland) · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Positron Emission Tomography (PET), as a non-invasive translatable imaging technology, can be incorporated into various stages of the CNS drug discovery process to provide valuable information for key preclinical and clinical decision-making. Novel CNS PET ligand discovery efforts in the industry setting, however, are facing unique challenges associated with lead design and prioritization, and budget constraints. In this review, three strategies aiming toward improving the central nervous system (CNS) PET ligand discovery process are described: first, early determination of receptor density (B
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.